



**Follow up Study on Attention Deficit
Hyperactivity Disorder Patients with and
Without Comorbid Mood Disorders
Receiving Non Stimulant Medication**

Thesis

*Submitted for Partial Fulfillment of
Master Degree in **Neuropsychiatry***

By

Yara Osama Mohamed Fahmy

MB, BCh Ain Shams University

Under Supervision of

Prof. Dr. Nermeen Mahmoud Shaker

Professor of Psychiatry

Faculty of Medicine - Ain Shams University

Prof. Dr. Doaa Helmy

Assistant Professor of Psychiatry

Faculty of Medicine - Ain Shams University

Dr. Ahmed Adel Abd Elgawad

Lecturer of Psychiatry

Faculty of Medicine - Ain Shams University

Faculty of Medicine - Ain Shams University

2019

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سبحانك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgments

*First and foremost, I feel always indebted to **Allah** the Most Beneficent and Merciful.*

*I wish to express my deepest thanks, gratitude and appreciation to **Prof. Dr. Nermeen Mahmoud Shaker**, Professor of Psychiatry, Faculty of Medicine, Ain Shams University, for her meticulous supervision, kind guidance, valuable instructions and generous help.*

*Special thanks are due to **Prof. Dr. Doaa Helmy**, Assistant Professor of Psychiatry, Faculty of Medicine, Ain Shams University, for her sincere efforts, fruitful encouragement.*

*I am deeply thankful to **Dr. Ahmed Adel Abd Elgawad**, Lecturer of Psychiatry, Faculty of Medicine, Ain Shams University, for his great help, outstanding support, active participation and guidance.*

*Thanks to **Mr. Mohamed Elweshy**, Clinical Psychologist at Ain Shams University for his great help all through this work.*

Yara Osama Mohamed Fahmy

List of Contents

Title	Page No.
List of Tables	5
List of Figures	7
List of Abbreviations.....	9
Introduction.....	- 1 -
Rationale of the Work	14
Hypothesis.....	15
Aim of the Work	16
Review of Literature	
▪ Comorbidity between ADHD and Mood Disorders	17
▪ Pathophysiology of ADHD and Mood Disorders.....	27
▪ Effect of Non Stimulant Medication on both of ADHD and mood symptoms	50
Patients and Methods	63
Results	71
Discussion.....	110
Strength.....	122
Limitations	123
Conclusion	124
Recommendations	125
Summary	127
References	133
Appendix.....	183
Arabic Summary	

List of Tables

Table No.	Title	Page No.
Tables of Review		
Table (1):	ATX suggested mechanisms of action	52
Table (2):	Potential advantages and disadvantages of ATX	62
Tables of Results		
Table (1):	Age, Gender and IQ of both groups.	71
Table (2):	Clinical criteria of both groups.	73
Table (3):	The change of the oppositional symptoms among the 2 groups using Conners' scale.....	75
Table (4):	The change of the symptoms of cognitive problem among the 2 groups using Conners' scale.	77
Table (5):	The change of hyperactivity among the 2 groups using Conners' scale.	79
Table (6):	The change of inattention among the 2 groups using Conners' scale.	81
Table (7):	The change of impulsivity among the 2 groups using Conners' scale.	83
Table (8):	The change of emotional lability among the 2 groups using Conners' scale.....	85
Table (9):	The change of the depressive symptoms among the 2 groups using CDI.	87
Table (10):	The change of the atypical symptoms among the 2 groups using the PBR scale.	89
Table (11):	The change of irritability among the 2 groups using the PBR scale.....	90

List of Tables cont..

Table No.	Title	Page No.
Table (12):	The change of grandiosity using the PBR scale among the 2 groups.	92
Table (13):	The change of hyperactivity using the PBR scale among the 2 groups.....	94
Table (14):	The change of aggression using the PBR scale among the 2 groups.	95
Table (15):	The change of inattention using the PBR scale among the 2 groups.	97
Table (16):	The change of affect symptoms using the PBR scale among the 2 groups.....	99
Table (17):	The change of social interactions symptoms using the PBR scale among the 2 groups.	101
Table (18):	The change of the total bipolar index score using the PBR scale among the 2 groups.....	103
Table (19):	Correlation between the total ADHD index, CDI score and Total Bipolar Index throughout the follow up.....	105

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Clinical criteria of both groups.....	73
Figure (2):	The change of the oppositional symptoms among the 2 groups using Conners' scale.....	75
Figure (3):	The change of the symptoms of cognitive problem among the 2 groups using Conners' scale.....	77
Figure (4):	Changes in hyperactivity among the 2 groups using Conners' scale.	79
Figure (5):	Changes of inattention among the 2 groups using Conners' scale.	81
Figure (6):	Changes in impulsivity among the 2 groups using Conners' scale.	83
Figure (7):	Changes in emotional liability among the 2 groups using Conners' scale.	85
Figure (8):	Changes in depressive symptoms among the 2 groups using CDI.....	87
Figure (9):	Changes in atypical symptoms using PBR scale among the 2 groups.	89
Figure (10):	Changes in irritability using PBR scale among the 2 groups.....	91
Figure (11):	Changes of grandiosity using the PBR scale among the 2 groups.....	92
Figure (12):	Changes of hyperactivity using the PBR scale among the 2 groups.....	94
Figure (13):	Changes of aggression using the PBR scale among the 2 groups.....	96

List of Figures cont..

Fig. No.	Title	Page No.
Figure (14):	Changes of inattention using the PBR scale among the 2 groups.....	98
Figure (15):	Changes of affect symptoms using the PBR scale among the 2 groups.....	99
Figure (16):	Changes of social interactions symptoms using the PBR scale among the 2 groups.....	101
Figure (17):	Changes of the total bipolar index score using the PBR scale among the 2 groups.....	103
Figure (18):	Correlation between the total ADHD index and the CDI score in the 2 nd visit.....	105
Figure (19):	Correlation between the total ADHD index and Total Bipolar Index in the 2 nd and 3 rd visit	106

List of Abbreviations

Abb.	Full term
<i>AAP</i>	<i>American Academy of Pediatrics.</i>
<i>ADHD</i>	<i>Attention deficit hyperactivity disorder.</i>
<i>ADHD-C</i>	<i>Attention deficit hyperactivity disorder - Combined type.</i>
<i>ADHD-I</i>	<i>Attention deficit hyperactivity disorder - Inattentive type.</i>
<i>ADHD-RSIV</i>	<i>Attention-Deficit Hyperactivity Disorder Rating Scale-IV.</i>
<i>ASD</i>	<i>Autistic spectrum disorder.</i>
<i>ATX</i>	<i>Atomoxetine.</i>
<i>BD</i>	<i>Bipolar disorder.</i>
<i>BPD</i>	<i>Bipolar disorder.</i>
<i>CADDRA</i>	<i>Canadian Attention Deficit Hyperactivity Disorder Resource Alliance.</i>
<i>CBT</i>	<i>Cognitive behavioral therapy.</i>
<i>CC</i>	<i>Corpus callosum.</i>
<i>CD</i>	<i>Conduct disorder.</i>
<i>CDI</i>	<i>Children Depression Inventory.</i>
<i>CDRS-R</i>	<i>Children's Depression Rating Scale-Revised.</i>
<i>CNS</i>	<i>Central nervous system.</i>
<i>CPRS-R:L</i>	<i>Conners' Parent Rating Scale-Revised: Long Version.</i>
<i>CSF</i>	<i>Cerebrospinal fluid.</i>
<i>DA</i>	<i>Dopamine.</i>
<i>DD</i>	<i>Developmental disorder.</i>
<i>DMDD</i>	<i>Disruptive Mood Dysregulation Disorder.</i>
<i>DSM-5</i>	<i>Diagnostic and Statistical Manual of Mental Disorders, fifth edition.</i>
<i>DTI</i>	<i>Diffusion tensor imaging.</i>
<i>EMs</i>	<i>Extensive metabolizers.</i>
<i>FDA</i>	<i>United States Food and drug administration.</i>

List of Abbreviations cont...

Abb.	Full term
<i>GIRK</i>	<i>G-protein-coupled inwardly rectifying potassium channels.</i>
<i>IQ</i>	<i>Intelligence Quotient.</i>
<i>K-SADS</i>	<i>The Kiddie Schedule for Affective Disorder and Schizophrenia for School Age Children.</i>
<i>MDD</i>	<i>Major depressive disorder.</i>
<i>MRI</i>	<i>Magnetic resonance imaging.</i>
<i>MTA</i>	<i>Multimodal Treatment Study of Children with ADHD.</i>
<i>NE</i>	<i>Nor-epinephrine.</i>
<i>NMDA</i>	<i>N-Methyl-D-aspartic acid</i>
<i>NNTH</i>	<i>Number needed to harm</i>
<i>NNTB</i>	<i>Number needed to treat in order to benefit</i>
<i>ODD</i>	<i>Oppositional Defiant Disorder.</i>
<i>PBR</i>	<i>Pediatric behavior rating scale.</i>
<i>PFC</i>	<i>Prefrontal cortex.</i>
<i>QoL</i>	<i>Quality of life.</i>
<i>SD</i>	<i>Standard deviation.</i>
<i>SMs</i>	<i>Slow metabolizers.</i>
<i>SPSS</i>	<i>Statistical Package for the Social Sciences.</i>
<i>SSRI</i>	<i>Selective serotonin reuptake inhibitors.</i>
<i>TADS</i>	<i>Treatment of Adolescent Depression Study.</i>
<i>TMAP</i>	<i>Texas Medication Algorithm Project.</i>
<i>TMS</i>	<i>Transcranial magnetic stimulation.</i>
<i>WM</i>	<i>White matter.</i>

INTRODUCTION

ADHD is a rather common condition that affects about 5 % of the children and adolescents and 2.5% of the adults (*Polanczyk et al., 2014*). ADHD frequently co-occurs with other psychiatric disorders (*Skirbekk et al., 2011*). It is characterized by cross-situational impairments in attention, activity and impulse control which in 60% of the childhood cases persists to adulthood (*Sibley et al., 2017*).

Young people with ADHD and depression are more impaired than those with ADHD or depression alone. Therefore, identifying young people with ADHD who are at risk of depression and other comorbid mood symptoms or disorders is important, in terms of facilitating early intervention or prevention (*Blackman et al., 2005*).

Mood symptoms such as irritability and its features are common in ADHD, even though it is not a defining diagnostic feature, it can be described as a propensity to react with anger, grouchiness, or tantrums disproportionate to the situation (*Stringaris et al., 2010*) and when included in the broader definition of emotional dysregulation, it is present in around 25-45% of children with ADHD (*Shaw et al., 2013*).

In recent years an “irritable” dimension of Oppositional Defiant Disorder (ODD) has been identified (*Stringaris et al., 2010*). This includes the items “often loses temper”, “is often

angry and resentful”, and “is often touchy or easily annoyed by others”, all of which are common in ADHD and all of them are considered mood symptoms (*Vidal-Ribas et al., 2016*).

More recently, severely impairing childhood chronic irritability has been conceptualized as a new diagnostic category in the mood disorders section of the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) (*American Psychiatric Association, 2013*). This new diagnostic category, known as Disruptive Mood Dysregulation Disorder (DMDD), is characterized by severe temper outbursts that are grossly out of proportion in intensity or duration to the situation. Alongside these temper outbursts the child experiences a persistently irritable or angry mood most of the day, nearly every day (*Copeland et al., 2013*).

Early research into DMDD in the general population, where existing data have been used to derive diagnoses retrospectively, suggests that the prevalence ranges from 0.8% to 3.3% (*Copeland et al., 2013*). Children with DMDD have been found to be very impaired, with high rates of comorbidity including depression (*Dougherty et al., 2014*). DMDD in the context of ADHD has not been studied widely. Results from community samples suggest that 4.3-23.5% of those with ADHD meet DMDD diagnostic criteria (*Copeland et al., 2013; Mulraney et al., 2016*). Therefore, the findings to date suggest that DMDD is more common in those with ADHD than in the general population (*Mulraney et al., 2016*).

The comparative efficacy and safety of pharmacological and non-pharmacological treatments are largely unknown, mainly because of the paucity of head-to-head trials. A wide variety of interventions have been used for the treatment of ADHD, including pharmacological and psychological interventions, herbal and homeopathic remedies, and dietary management (*Catala-LoÁpez et al., 2017*).

Stimulant medications (e.g., amphetamine, and methylphenidate) and non-stimulant medications (e.g., atomoxetine, guanfacine and clonidine) are the two categories of medications approved for treating ADHD. Among these, long term treatment with atomoxetine and methylphenidate is not only proven to be clinically efficacious, but also improves a wide range of executive functions and focused attention among children with ADHD (*Gau and Shang, 2010*).

Atomoxetine as a non-stimulant treatment, approved in the United States for the treatment of ADHD in November 2002, it is a non-stimulant that is thought to act presynaptically via the inhibition of norepinephrine reuptake. Atomoxetine has limited effect on the serotonin or dopamine transporters and has low affinity at dopaminergic, muscarinic-cholinergic, histaminic, serotonergic and α_1 - or α_2 -adrenergic receptors (*Spencer et al., 2002*).

RATIONALE OF THE WORK

ADHD is a chronic disorder that may affect all aspects of a child's life including academic difficulties and social skills problems. It also causes a burden on families and society, which makes it a major public health problem. ADHD is very often associated with other comorbidities, particularly mood and anxiety disorders. Comorbid disorders, recognized or unrecognized, may also complicate the treatment process. However, there are a relatively few studies were conducted to assess the effect of ADHD associated comorbidities on the treatment process. In this study, Non-stimulant treatment (Atomoxetine) was chosen because of its availability and continuity at Ain Shams university child psychiatry clinics.

HYPOTHESIS

In this study it was expected that the presence of comorbid mood disorder with ADHD will affect or decrease the response of ADHD symptoms to non-stimulant treatment.